Possible association of CAG repeat polymorphism in KCNN3 encoding the potassium channel SK3 with oxaliplatin-induced neurotoxicity

Cancer Chemother Pharmacol. 2018 Jul;82(1):149-157. doi: 10.1007/s00280-018-3600-1. Epub 2018 May 17.

Abstract

Introduction: Data suggest a role of the potassium channel SK3 (KCNN3 gene) in oxaliplatin-induced neurotoxicity (OIN). Length variations in the polymorphic CAG repeat of the KCNN3 gene may be associated with the risk of OIN.

Materials and methods: We performed patch-clamp experiments on HEK293 cell lines, expressing SK3 channel isoforms with short (11) or long (24) CAG repetitions, to measure intracellular calcium concentrations to test the effects of oxaliplatin on current density. A retrospective study was carried out on patients with colorectal cancer who had received oxaliplatin-based chemotherapy. DNA for KCNN3 genotyping was extracted from leukocytes. The region containing the CAG repeats was amplified by PCR and the products separated by capillary electrophoresis for length analysis. The patients were divided into three groups depending on whether they carried two short alleles, one short allele and one long allele, or two long alleles. The primary endpoint was the onset of grade 2 or 3 neuropathy to oxaliplatin.

Results: There was no difference in current density, but oxaliplatin induced a differential effect on apamin-sensitive current density between the two isoforms expressed in the HEK cell lines. There was a significant reduction of store-operated calcium entry into cells expressing the short and more active isoform only after high concentration of oxaliplatin exposition. Eighty-six patients were included in the clinical study. There was no significant association between OIN and KCNN3 polymorphism for the three groups.

Conclusion: We observed a slight association between OIN and CAG repeat polymorphisms of the KCNN3 gene in a preclinical model, but not a clinical study.

Keywords: KCNN3; Neuropathy; Oxaliplatin; Platinum; SK3 channel.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Female
  • Fluorouracil / administration & dosage
  • HEK293 Cells
  • Humans
  • Leucovorin / administration & dosage
  • Male
  • Middle Aged
  • Neurotoxicity Syndromes / blood
  • Neurotoxicity Syndromes / etiology
  • Neurotoxicity Syndromes / genetics*
  • Organoplatinum Compounds / administration & dosage
  • Oxaliplatin / administration & dosage
  • Oxaliplatin / adverse effects*
  • Patch-Clamp Techniques
  • Polymorphism, Genetic
  • Small-Conductance Calcium-Activated Potassium Channels / genetics*
  • Trinucleotide Repeats

Substances

  • Antineoplastic Agents
  • KCNN3 protein, human
  • Organoplatinum Compounds
  • Small-Conductance Calcium-Activated Potassium Channels
  • Oxaliplatin
  • Leucovorin
  • Fluorouracil

Supplementary concepts

  • Folfox protocol